Celldex Therapeutics (CLDX) Equity Average (2011 - 2026)

Celldex Therapeutics' Equity Average history runs 16 years deep, the most recent figure standing at $491.7 million for Q1 2026.

• In Q1 2026, Equity Average fell 32.18% year-over-year to $491.7 million; the TTM figure through Mar 2026 stood at $491.7 million (down 32.18% YoY), while the FY2025 annual figure was $637.1 million, up 8.33% from the prior year.
• Equity Average was $491.7 million for Q1 2026 at Celldex Therapeutics, down from $562.8 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $826.1 million in Q2 2024 to a low of $262.1 million in Q3 2023.
• Historically, Equity Average has averaged $517.5 million across 5 years, with a median of $491.7 million in 2026.
• The sharpest annual moves came in 2024 and 2026: Equity Average surged 205.11% in 2024, then tumbled 32.18% in 2026.
• A 5-year view of Equity Average shows it stood at $335.8 million in 2022, then climbed by 0.64% to $337.9 million in 2023, then soared by 126.8% to $766.5 million in 2024, then slipped by 26.58% to $562.8 million in 2025, then dropped by 12.63% to $491.7 million in 2026.
• The last three Equity Average figures came in at $491.7 million (Q1 2026), $562.8 million (Q4 2025), and $626.9 million (Q3 2025), per Business Quant data.